Tag: equity
-
Lilly Acquires Migraine Therapy Company in $960M Deal
Drug maker Eli Lilly and Company is acquiring CoLucid Pharmaceuticals, a developer of treatments for migraine pain and associated symptoms.
-
Univ. Spin-Off Develops Lower Cost 3-D Metal Printing
A spin-off enterprise from University at Buffalo engineering school developed a machine that produces lower-cost aluminum parts with three-dimensional liquid metal printing.
-
Ionis Options Cardiac Drugs in $1.5 Billion Deal
Biotechnology company Ionis Pharmaceuticals is providing drug maker Novartis first access to two experimental drugs for controlling proteins that promote cholesterol and triglycerides, which contribute to heart disease.
-
Precision Health Tech Network Expands, Invests $400M
Digital Life Alliance, a consortium of enterprises applying advanced technologies to health and medicine that plans to offer personalized solutions, is expanding to 7 members, as well as iCarbonX, the company that founded the network.
-
Smartphone System Shown to Control Blood Glucose Levels
A bionic pancreas system using a smartphone was shown in a clinical trial to control blood glucose levels better than a commercial insulin pump in persons with type 1 diabetes.
-
Stem Cell Therapy Company Formed, Staked to $225M
A pharmaceutical company and health care venture investor are forming BlueRock Therapeutics, a biotechnology enterprise to design regenerative medicine treatments with stem cells.
-
Start-Up Reprogramming Stem Cells to Treat Heart Failure
A new enterprise, spun-off from the Gladstone Institutes in San Francisco, plans to regenerate heart muscle from other cells to treat heart failure.
-
Company Launches to Discover Gut-Brain Therapies
A California Institute of Technology biologist is starting a new enterprise to discover treatments for neurological disorders through pathways originating in the gut.
-
Novartis Acquires Sickle-Cell Drug Developer
Drug maker Novartis is acquiring Selexys Pharmaceuticals Corp., a developer of treatments for pain episodes associated with sickle cell disease, for $665 million.
-
Blood Stem Cell Start-Up Launches, Earns $48.5M Funding
A new enterprise, spun-off from Harvard University stem cell labs, aims to make stem cell transplants from bone marrow safer and more reliable.